Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

FDA Approves Alnylam’s Amvuttra for hATTR Amyloidosis Polyneuropathy

FDA Approves Alnylam’s Amvuttra for hATTR Amyloidosis Polyneuropathy

The FDA approved Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis, a rare inherited disease caused by mutations in the TTR gene.

The agency approval was supported by positive results from a phase 3 clinical trial that enrolled 164 participants. Those who received Amvuttra had significant improvements compared with the placebo group, and half of the treated participants experienced improvements in neuropathy impairment relative to baseline by nine months.

The approved indication for Amvuttra requires an injection treatment in patients once every three months.

June 15, 2022

https://www.fdanews.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies